{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:12:19Z","timestamp":1785892339170,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,2,17]],"date-time":"2007-02-17T00:00:00Z","timestamp":1171670400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1007\/s10875-007-9070-6","type":"journal-article","created":{"date-parts":[[2007,2,16]],"date-time":"2007-02-16T14:14:06Z","timestamp":1171635246000},"page":"210-220","source":"Crossref","is-referenced-by-count":22,"title":["Immunomodulatory Drug CC-4047 is a Cell-type and Stimulus-Selective Transcriptional Inhibitor of Cyclooxygenase 2"],"prefix":"10.1007","volume":"27","author":[{"given":"Gregory D.","family":"Ferguson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Jensen-Pergakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice","family":"Wilkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvi","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Normand","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Verhelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure Moutouh","family":"De Parseval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura G.","family":"Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,2,17]]},"reference":[{"key":"9070_CR1","volume-title":"Lipid-derived autacoids","author":"E Smyth","year":"2005","unstructured":"Smyth E, Burke A, FitzGerald GA: Lipid-derived autacoids. New York, NY, USA, McGraw-Hill 2005"},{"key":"9070_CR2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.biochem.69.1.145","volume":"69","author":"WL Smith","year":"2000","unstructured":"Smith WL, DeWitt DL, Garavito RM: Cyclooxygenases: Structural, cellular, and molecular biology. Annu Rev Biochem 69:145\u2013182, 2000","journal-title":"Annu Rev Biochem"},{"key":"9070_CR3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1517\/14728214.10.1.53","volume":"10","author":"JT Merrill","year":"2005","unstructured":"Merrill JT: Emergence of targeted immune therapies for systemic lupus. Expert Opin Emerg Drugs 10:53\u201365, 2005","journal-title":"Expert Opin Emerg Drugs"},{"key":"9070_CR4","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2165\/00003495-200262080-00003","volume":"62","author":"SK Ballas","year":"2002","unstructured":"Ballas SK: Sickle cell anaemia: Progress in pathogenesis and treatment. Drugs 62:1143\u20131172, 2002","journal-title":"Drugs"},{"key":"9070_CR5","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0950-3579(05)80316-4","volume":"9","author":"V Strand","year":"1995","unstructured":"Strand V: Innovative treatment approaches for rheumatoid arthritis. Issues in clinical trials of biological agents. Baillieres Clin Rheumatol 9:825\u2013835, 1995","journal-title":"Baillieres Clin Rheumatol"},{"key":"9070_CR6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nm1005","volume":"10","author":"L Xu","year":"2004","unstructured":"Xu L, Zhang L, Yi Y, Kang HK, Datta SK: Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat Med 10:411\u2013415, 2004","journal-title":"Nat Med"},{"key":"9070_CR7","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1172\/JCI200421633","volume":"114","author":"DK Kaul","year":"2004","unstructured":"Kaul DK, Liu XD, Chang HY, Nagel RL, Fabry ME: Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J Clin Invest 114:1136\u20131145, 2004","journal-title":"J Clin Invest"},{"key":"9070_CR8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2174\/1568026054201695","volume":"5","author":"MC Hochberg","year":"2005","unstructured":"Hochberg MC: COX-2 selective inhibitors in the treatment of arthritis: A rheumatologist perspective. Curr Top Med Chem 5:443\u2013448, 2005","journal-title":"Curr Top Med Chem"},{"key":"9070_CR9","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.4049\/jimmunol.165.5.2790","volume":"165","author":"MJ Bidgood","year":"2000","unstructured":"Bidgood MJ, Jamal OS, Cunningham AM, Brooks PM, Scott KF: Type IIA secretory phospholipase A2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes. J Immunol 165:2790\u20132797, 2000","journal-title":"J Immunol"},{"key":"9070_CR10","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S1086-5802(16)30394-1","volume":"38","author":"AA Schuna","year":"1998","unstructured":"Schuna AA: Update on treatment of rheumatoid arthritis. J Am Pharm Assoc (Wash) 38:728\u2013735; quiz 735\u2013727, 1998","journal-title":"J Am Pharm Assoc (Wash)"},{"key":"9070_CR11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI27291","volume":"116","author":"T Grosser","year":"2006","unstructured":"Grosser T, Fries S, FitzGerald GA: Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 116:4\u201315, 2006","journal-title":"J Clin Invest"},{"key":"9070_CR12","doi-asserted-by":"crossref","unstructured":"Kumar S, Rajkumar SV: Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer 2006","DOI":"10.1016\/j.ejca.2006.04.004"},{"key":"9070_CR13","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood-2005-08-3450","volume":"107","author":"G Anderson","year":"2006","unstructured":"Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V, Donnenberg A, Ghobrial I, Mapara MY, Stirling D, Roodman D, Lentzsch S: Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 107:3098\u20133105, 2006","journal-title":"Blood"},{"key":"9070_CR14","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-05-0577","volume":"11","author":"FJ Hernandez-Ilizaliturri","year":"2005","unstructured":"Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS: Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 11:5984\u20135992, 2005","journal-title":"Clin Cancer Res"},{"key":"9070_CR15","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","volume":"173","author":"EP Sampaio","year":"1991","unstructured":"Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173:699\u2013703, 1991","journal-title":"J Exp Med"},{"key":"9070_CR16","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1073\/pnas.0409578102","volume":"102","author":"P Labhart","year":"2005","unstructured":"Labhart P, Karmakar S, Salicru EM, Egan BS, Alexiadis V, O\u2019Malley BW, Smith CL: Identification of target genes in breast cancer cells directly regulated by the SRC-3\/AIB1 coactivator. Proc Natl Acad Sci USA 102:1339\u20131344, 2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"9070_CR17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cellimm.2004.09.003","volume":"230","author":"F Payvandi","year":"2004","unstructured":"Payvandi F, Wu L, Haley M, Schafer PH, Zhang LH, Chen RS, Muller GW, Stirling DI: Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol 230:81\u201388, 2004","journal-title":"Cell Immunol"},{"key":"9070_CR18","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1476-5381.1995.tb15091.x","volume":"116","author":"MR Panara","year":"1995","unstructured":"Panara MR, Greco A, Santini G, Sciulli MG, Rotondo MT, Padovano R, di Giamberardino M, Cipollone F, Cuccurullo F, Patrono C, et\u00a0al.: Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphonamido-6-(2,4-difluorothio-phenyl)-1-inda none (L-745,337), on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases. Br J Pharmacol 116:2429\u20132434, 1995","journal-title":"Br J Pharmacol"},{"key":"9070_CR19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0076-6879(03)76023-6","volume":"376","author":"BE Bernstein","year":"2004","unstructured":"Bernstein BE, Humphrey EL, Liu CL, Schreiber SL: The use of chromatin immunoprecipitation assays in genome-wide analyses of histone modifications. Methods Enzymol 376:349\u2013360, 2004","journal-title":"Methods Enzymol"},{"key":"9070_CR20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cell.2006.02.043","volume":"125","author":"TI Lee","year":"2006","unstructured":"Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, Chevalier B, Johnstone SE, Cole MF, Isono K, Koseki H, Fuchikami T, Abe K, Murray HL, Zucker JP, Yuan B, Bell GW, Herbolsheimer E, Hannett NM, Sun K, Odom DT, Otte AP, Volkert TL, Bartel DP, Melton DA, Gifford DK, Jaenisch R, Young RA: Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125:301\u2013313, 2006","journal-title":"Cell"},{"key":"9070_CR21","doi-asserted-by":"crossref","first-page":"9287","DOI":"10.1074\/jbc.M512956200","volume":"281","author":"LJ Benson","year":"2006","unstructured":"Benson LJ, Gu Y, Yakovleva T, Tong K, Barrows C, Strack CL, Cook RG, Mizzen CA, Annunziato AT: Modifications of H3 and H4 during chromatin replication, nucleosome assembly, and histone exchange. J Biol Chem 281:9287\u20139296, 2006","journal-title":"J Biol Chem"},{"key":"9070_CR22","doi-asserted-by":"crossref","first-page":"18091","DOI":"10.1074\/jbc.M311786200","volume":"279","author":"F Miao","year":"2004","unstructured":"Miao F, Gonzalo IG, Lanting L, Natarajan R: In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem 279:18091\u201318097, 2004","journal-title":"J Biol Chem"},{"key":"9070_CR23","doi-asserted-by":"crossref","first-page":"L956","DOI":"10.1152\/ajplung.00338.2003","volume":"286","author":"GY Park","year":"2004","unstructured":"Park GY, Joo M, Pedchenko T, Blackwell TS, Christman JW: Regulation of macrophage cyclooxygenase-2 gene expression by modifications of histone H3. Am J Physiol Lung Cell Mol Physiol 286:L956\u2013L962, 2004","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"9070_CR24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1096\/fasebj.13.2.245","volume":"13","author":"LC Hamilton","year":"1999","unstructured":"Hamilton LC, Mitchell JA, Tomlinson AM, Warner TD: Synergy between cyclo-oxygenase-2 induction and arachidonic acid supply in vivo: Consequences for nonsteroidal antiinflammatory drug efficacy. Faseb J 13:245\u2013251, 1999","journal-title":"Faseb J"},{"key":"9070_CR25","doi-asserted-by":"crossref","first-page":"34256","DOI":"10.1074\/jbc.M402594200","volume":"279","author":"CA Rouzer","year":"2004","unstructured":"Rouzer CA, Kingsley PJ, Wang H, Zhang H, Morrow JD, Dey SK, Marnett LJ: Cyclooxygenase-1-dependent prostaglandin synthesis modulates tumor necrosis factor-alpha secretion in lipopolysaccharide-challenged murine resident peritoneal macro-phages. J Biol Chem 279:34256\u201334268, 2004","journal-title":"J Biol Chem"},{"key":"9070_CR26","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMp048288","volume":"351","author":"GA Fitzgerald","year":"2004","unstructured":"Fitzgerald GA: Coxibs and cardiovascular disease. N Engl J Med 351:1709\u20131711, 2004","journal-title":"N Engl J Med"},{"key":"9070_CR27","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.4049\/jimmunol.166.3.2018","volume":"166","author":"E Faure","year":"2001","unstructured":"Faure E, Thomas L, Xu H, Medvedev A, Equils O, Arditi M: Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol 166:2018\u20132024, 2001","journal-title":"J Immunol"},{"key":"9070_CR28","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1128\/CDLI.10.4.558-563.2003","volume":"10","author":"CS Oude Nijhuis","year":"2003","unstructured":"Oude Nijhuis CS, Vellenga E, Daenen SM, Kamps WA, De Bont ES: Endothelial cells are main producers of interleukin 8 through Toll-like receptor 2 and 4 signaling during bacterial infection in leukopenic cancer patients. Clin Diagn Lab Immunol 10:558\u2013563, 2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"9070_CR29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0167-4889(02)00320-8","volume":"1592","author":"MU Martin","year":"2002","unstructured":"Martin MU, Wesche H: Summary and comparison of the signaling mechanisms of the Toll\/interleukin-1 receptor family. Biochim Biophys Acta 1592:265\u2013280, 2002","journal-title":"Biochim Biophys Acta"},{"key":"9070_CR30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1124\/mol.52.5.829","volume":"52","author":"GM Greig","year":"1997","unstructured":"Greig GM, Francis DA, Falgueyret JP, Ouellet M, Percival MD, Roy P, Bayly C, Mancini JA, O\u2019Neill GP: The interaction of arginine 106 of human prostaglandin G\/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugs. Mol Pharmacol 52:829\u2013838, 1997","journal-title":"Mol Pharmacol"},{"key":"9070_CR31","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1182\/blood.V92.7.2551","volume":"92","author":"E Graido-Gonzalez","year":"1998","unstructured":"Graido-Gonzalez E, Doherty JC, Bergreen EW, Organ G, Telfer M, McMillen MA: Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood 92:2551\u20132555, 1998","journal-title":"Blood"},{"key":"9070_CR32","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2141.1994.tb08316.x","volume":"87","author":"J Kurantsin-Mills","year":"1994","unstructured":"Kurantsin-Mills J, Ibe BO, Natta CL, Raj JU, Siegel RS, Lessin LS: Elevated urinary levels of thromboxane and prostacyclin metabolities in sickle cell disease reflects activated platelets in the circulation. Br J Haematol 87:580\u2013585, 1994","journal-title":"Br J Haematol"},{"key":"9070_CR33","doi-asserted-by":"crossref","unstructured":"de Parseval L: Selected IMIDs\u00ae Immunomodulatory drugs: New approaches to the regulation of erythropoiesis and hemoglobin synthesis in b-hemoglobinopathies. In 11th Congress of the European Hematology Association, Amsterdam, The Netherlands, 2006","DOI":"10.1182\/blood.V106.11.2702.2702"},{"key":"9070_CR34","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/dvdy.20802","volume":"235","author":"BS Pace","year":"2006","unstructured":"Pace BS, Zein S: Understanding mechanisms of gamma-globin gene regulation to develop strategies for pharmacological fetal hemoglobin induction. Dev Dyn 235:1727\u20131737, 2006","journal-title":"Dev Dyn"},{"key":"9070_CR35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1046\/j.1365-2141.2003.04594.x","volume":"123","author":"EA Manci","year":"2003","unstructured":"Manci EA, Culberson DE, Yang YM, Gardner TM, Powell R, Haynes J, Jr., Shah AK, Mankad VN: Causes of death in sickle cell disease: An autopsy study. Br J Haematol 123:359\u2013365, 2003","journal-title":"Br J Haematol"},{"key":"9070_CR36","first-page":"1071","volume":"16","author":"N Yanaka","year":"2005","unstructured":"Yanaka N, Koyama TA, Komatsu S, Nakamura E, Kanda M, Kato N: Vitamin B6 suppresses NF-kappaB activation in LPS-stimulated mouse macrophages. Int J Mol Med 16:1071\u20131075, 2005","journal-title":"Int J Mol Med"},{"key":"9070_CR37","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.bcp.2005.05.003","volume":"70","author":"DX Hou","year":"2005","unstructured":"Hou DX, Yanagita T, Uto T, Masuzaki S, Fujii M: Anthocyanidins inhibit cyclooxygenase-2 expression in LPS-evoked macrophages: Structure-activity relationship and molecular mechanisms involved. Biochem Pharmacol 70:417\u2013425, 2005","journal-title":"Biochem Pharmacol"},{"key":"9070_CR38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bbrc.2005.08.059","volume":"336","author":"KY Ahn","year":"2005","unstructured":"Ahn KY, Kim BH, Lee YR, Hwang DH, Chung EY, Min KR, Kim Y: Dual inhibitory effects of furonaphthoquinone compound on enzyme activity and lipopolysaccharide-induced expression of cyclooxygenase-2 in macrophages. Biochem Biophys Res Commun 336:93\u201399, 2005","journal-title":"Biochem Biophys Res Commun"},{"key":"9070_CR39","doi-asserted-by":"crossref","first-page":"27406","DOI":"10.1016\/S0021-9258(19)61525-5","volume":"275","author":"AL Welm","year":"2000","unstructured":"Welm AL, Mackey SL, Timchenko LT, Darlington GJ, Timchenko NA: Translational induction of liver-enriched transcriptional inhibitory protein during acute phase response leads to repression of CCAAT\/enhancer binding protein alpha mRNA. J Biol Chem 275:27406\u201327413, 2000","journal-title":"J Biol Chem"},{"key":"9070_CR40","doi-asserted-by":"crossref","first-page":"6259","DOI":"10.1074\/jbc.275.9.6259","volume":"275","author":"DJ Wadleigh","year":"2000","unstructured":"Wadleigh DJ, Reddy ST, Kopp E, Ghosh S, Herschman HR: Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages. J Biol Chem 275:6259\u20136266, 2000","journal-title":"J Biol Chem"},{"key":"9070_CR41","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1096\/fj.05-5360com","volume":"20","author":"HT Aung","year":"2006","unstructured":"Aung HT, Schroder K, Himes SR, Brion K, van Zuylen W, Trieu A, Suzuki H, Hayashizaki Y, Hume DA, Sweet MJ, Ravasi T: LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression. Faseb J 20:1315\u20131327, 2006","journal-title":"Faseb J"},{"key":"9070_CR42","first-page":"3349","volume":"7","author":"J Fujita","year":"2001","unstructured":"Fujita J, Mestre JR, Zeldis JB, Subbaramaiah K, Dannenberg AJ: Thalidomide and its analogues inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2. Clin Cancer Res 7:3349\u20133355, 2001","journal-title":"Clin Cancer Res"},{"key":"9070_CR43","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1600-0609.2004.00393.x","volume":"74","author":"M Streetly","year":"2005","unstructured":"Streetly M, Hunt BJ, Parmar K, Jones R, Zeldis J, Schey S: Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis. Eur J Haematol 74:293\u2013296, 2005","journal-title":"Eur J Haematol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-007-9070-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10875-007-9070-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-007-9070-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T21:03:11Z","timestamp":1628456591000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-007-9070-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,17]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["9070"],"URL":"https:\/\/doi.org\/10.1007\/s10875-007-9070-6","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,17]]}}}